PTGX Shares Outstanding History



Below is a table of the PTGX shares outstanding history going back to 8/10/2016:

Date PTGX Shares Outstanding
8/10/201614.66M
8/31/201616.46M
10/31/201616.71M
2/28/201716.79M
4/28/201716.86M
7/31/201716.90M
10/31/201720.48M
2/28/201821.10M
4/30/201821.20M
7/31/201821.22M
10/31/201824.19M
2/28/201923.35M
4/30/201923.40M
7/31/201926.28M
3/7/201915.33M
10/31/201927.21M
2/28/202027.29M
4/30/202027.43M
7/31/202036.81M
10/30/202038.26M
2/26/202143.81M
4/30/202143.95M
7/30/202147.55M
10/29/202147.73M
2/15/202248.41M
4/29/202248.66M
7/28/202249.08M
10/31/202249.20M
3/2/202351.28M
4/28/202357.25M
7/31/202357.53M
10/27/202357.68M
2/22/202458.27M

Also see: PTGX Market Cap History
PTGX YTD Return
PTGX Historical Shares Outstanding:
+20.09% CAGR
PTGX Historical Shares Outstanding: +20.09% CAGR

Mouse over chart for data details
8/10/2016 ...2/22/2024
Protagonist Therapeutics is a clinical-stage biopharmaceutical company with various peptide-based new chemical entities in different stages of development, all derived from Co.'s proprietary technology platform. Co.'s clinical programs address two main categories of diseases; hematology and blood disorders, and inflammatory and immunomodulatory diseases. Co.'s main clinical asset, rusfertide (generic name for PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of erythrocytosis, iron overload and other blood disorders. PN-943 is an investigational, orally delivered, gut-restricted alpha-4-beta-7 specific integrin antagonist for inflammatory bowel disease. We show 33 historical shares outstanding datapoints in our coverage of PTGX's shares outstanding history.

Understanding the changing numbers of PTGX shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like PTGX versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching PTGX by allowing them to research PTGX shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree PTGX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Protagonist Therapeutics (PTGX) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

PTI Shares Outstanding History
PTIE Shares Outstanding History
PTIX Shares Outstanding History
PTLA Shares Outstanding History
PTPI Shares Outstanding History
PTX Shares Outstanding History
PULM Shares Outstanding History
PXMD Shares Outstanding History
PYXS Shares Outstanding History
QDEL Shares Outstanding History
More Healthcare companies »

 

PTGX Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2024, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.